3 Stocks to Buy According to Devesh Gandhi’s SilverArc Capital
In this article, we will discuss the top 3 stocks to buy according to Devesh Gandhi’s SilverArc Capital.
Posts Tagged ‘NASDAQ:DRNA’
Hedge Funds Are Selling Dicerna Pharmaceuticals Inc (DRNA)
Is Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the...
Should You Now Consider Selling Your Dicerna Pharmaceuticals (DRNA) Shares?
Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” third quarter 2021 investor letter – a copy of which can be ...
Hedge Fund Sentiment Is Stagnant On Dicerna Pharmaceuticals Inc (DRNA)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
5 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie
In this article, we will discuss 5 pharmaceutical stocks to buy today according to Tiger Cub Billionaire Lee Ainslie.
Do Hedge Funds Love Dicerna Pharmaceuticals Inc (DRNA)?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end...
Is DRNA Stock A Buy or Sell?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money ...
Is DRNA A Good Stock To Buy Now According To Hedge Funds?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end...
Is Dicerna Pharmaceuticals (DRNA) a Smart Long-term Buy?
Baron Health Care Fund recently published its third-quarter commentary – a copy of which can be downloaded here.
Was The Smart Money Wrong About Piling Into Dicerna Pharmaceuticals Inc (DRNA)?
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.
5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)
Marc Schneidman’s Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010.
Hedge Funds Have Never Been This Bullish On Dicerna Pharmaceuticals Inc (DRNA)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file ...
Did Hedge Funds Make The Right Call On Dicerna Pharmaceuticals Inc (DRNA) ?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Aren’t Crazy About Dicerna Pharmaceuticals Inc (DRNA) Anymore
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
Were Hedge Funds Right About Dicerna Pharmaceuticals Inc (DRNA)?
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds.
Hedge Fund and Insider Trading News: David Tepper, Blue Harbour Group, ValueAct Capital, Schmitt Industries, Inc. (SMIT), Continental Resources, Inc. (CLR), and More
Here is how the activist hedge fund fared with its investment in Investors Bancorp, which accounted for 18 percent of its U.S. long assets.
Hedge Funds Have Never Been More Bullish On Dicerna Pharmaceuticals Inc (DRNA)
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November.
Is Dicerna Pharmaceuticals Inc (DRNA) A Good Stock To Buy?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Here’s What Hedge Funds Think About Dicerna Pharmaceuticals Inc (DRNA)
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period.
Hedge Funds Have Never Been More Bullish On Dicerna Pharmaceuticals Inc (DRNA)
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in...
Here is What Hedge Funds Think About Dicerna Pharmaceuticals Inc (DRNA)
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive...
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
Please follow RA Capital Management (if you aren't already doing so) to get real-time email alerts whenever we publish an article about RA Capital Management or update its stock...
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
Please follow RA Capital Management (if you aren't already doing so) to get real-time email alerts whenever we publish an article about RA Capital Management or update its stock...
13G Filing: EcoR1 Capital and Dicerna Pharmaceuticals Inc (DRNA)
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Oleg Nodelman's EcoR1 Capital filed an amended 13D.
You can check out EcoR1 Capital's latest holdings and filings here.
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
Please follow RA Capital Management (if you aren't already doing so) to get real-time email alerts whenever we publish an article about RA Capital Management or update its stock...
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
Please follow RA Capital Management (if you aren't already doing so) to get real-time email alerts whenever we publish an article about RA Capital Management or update its stock...
13D Filing: Bain Capital Life Sciences Fund, L.P. and Dicerna Pharmaceuticals Inc (DRNA)
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240....
13D Filing: Bain Capital Life Sciences Fund, L.p. and Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240....
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
You can access the original SEC filing by clicking here.
Micro-Cap Biotech Focus: Dicerna Pharmaceuticals Inc (DRNA) Presents Its Exciting New Drug Platform GalXC
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is a biopharmaceutical company that focuses on a technology called RNA interference (RNAi).
Do Hedge Funds Love Dicerna Pharmaceuticals Inc (DRNA)?
The successful funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous ...
Hedge Funds Aren’t Crazy About Dicerna Pharmaceuticals Inc (DRNA) Anymore
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in the third quarter, blaming macroeconomic conditions and unpredictable events...
RA Capital Is Expecting A Breakthrough Cardiovascular Drug From This Biotech
The biotechnology industry is up by more than 50% over the last year, but these towering returns don't come without great risk and volatility.
Entegris Inc (ENTG), Dicerna Pharmaceuticals Inc (DRNA): GMT Capital and Deerfield Management Report Their Latest Moves
In two new filings, Thomas E. Claugus' GMT Capital disclosed further raising its exposure to Entegris Inc (NASDAQ:ENTG).
Ra Capital Management Revealed Stake in Dicerna Pharmaceuticals Inc (DRNA) After Deerfield and Brookside
Ra Capital Management, a fund managed by Peter Kolchinsky, disclosed, in a new filing with the Securities and Exchange Commission, that it owns 2.43 million shares of Dicerna ...
Deerfield Management & Brookside Capital Revealed Significant Stakes in Newly Public Dicerna Pharmaceuticals Inc (DRNA)
In a couple of filings with the Securities and Exchange Commission, Deerfield Management, led by James E.
